

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Teikoku Pharma USA Inc.	06/17/2010
RECEIVING PARTY DATA	
Name:	Teikoku Seiyaku Kabushiki Kaisha
Street Address:	567 Sanbonatsu
Internal Address:	Ochi-Cho, Okawa-Gun
City:	Kagawa
State/Country:	JAPAN
Postal Code:	769-26
PROPERTY NUMBERS Total: 2	
Property Type	Number
Application Number:	60445572
Application Number:	10754477
CORRESPONDENCE DATA	
Fax Number:	(650)327-3231
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	650-327-3400
Email:	millsaps@bozpat.com
Correspondent Name:	Bozicevic, Field & Francis LLP
Address Line 1:	1900 University Avenue
Address Line 2:	Suite 200
Address Line 4:	East Palo Alto, CALIFORNIA 94303
ATTORNEY DOCKET NUMBER:	TEIK-007PRV & TEIK-007
NAME OF SUBMITTER:	Bret E. Field
Total Attachments: 1 source=TEIK-007_Exe_Assignment#page1.tif	

OP \$80.00 60445572

PATENT

501217955

REEL: 024605 FRAME: 0130

ASSIGNMENT OF APPLICATION

Atty Docket No. TEIK-007
& Atty Docket No. TEIK-007PRV

THIS ASSIGNMENT, by Teikoku Pharma USA, Inc. (hereinafter referred to as the assignor), having its principal place of business at 1718 Ringwood Avenue, San Jose, California 95131-1711, witnesseth:

WHEREAS, the said assignor has acquired right, title and interest for the United States and its territorial possessions and in all foreign countries in and to, any and all improvements which are disclosed in the invention entitled:

"Methods of Administering a Dermatological Agent to a Subject"

- X filed on January 8, 2004 as U.S. Application Serial No. 10/754,477 by virtue of an assignment from the inventors John Koo, Jutaro Shudo and Sadanobu Shirai to Teikoku Pharma USA, Inc. recorded on June 16, 2004, 014735/0448 (reel/frame), and
- X filed on February 7, 2003 as U.S. Application Serial No. 60/445,572 by virtue of an assignment from the inventors John Koo, Jutaro Shudo and Sadanobu Shirai to Teikoku Pharma USA, Inc. recorded on May 15, 2003, 013658/0393 (reel/frame), and

WHEREAS, Teikoku Seiyaku Kabushiki Kaisha, a corporation duly organized under and pursuant to the laws of Japan, and having its principal place of business at 567, Sanbonmatsu, Ochi-Cho, Okawa-Gun, Kagawa, 769-26 Japan (hereinafter referred to as the assignee) is desirous of acquiring an undivided one-half interest assignor's right, title and interest in and to said invention and said application for Letters Patent of the United States, and in and to any Letters Patent or Patents, United States or foreign, to be obtained therefore and thereon such that said assignor and assignee will each hold an undivided one-half interest in said invention:

NOW THEREFORE, for good and sufficient considerations, the receipt of which is hereby acknowledged, said assignor has sold, assigned, transferred and set over, and by these presents does sell, assign, transfer and set over, unto the assignee, its successors, legal representatives and assigns, an undivided one-half interest in its entire right title and interest in and to the above-mentioned invention, application for Letters Patent, and any and all Letters Patent or Patents in the United States of America and all foreign countries which may be granted therefore and thereon, and in and to any and all divisions, continuations, and continuations-in-part of said application, or reissues or extensions of said Letters Patent or Patents, and all rights under the International Convention for the Protection of Industrial Property, the undivided one-half interest to be held and enjoyed by said assignee, for its own use and behalf and the use and behalf of its successors, legal representatives and assigns, to the full end of the term or terms for which Letters Patent or Patents may be granted, as fully and entirely as the same would have been held and enjoyed by the assignor, had this sale and assignment not been made, such that said assignor and assignee each hold an undivided one-half interest in said invention.

AND for the same consideration, said assignor hereby covenants and agrees to and with said assignee, its successors, legal representatives and assigns, that, at the time of execution and delivery of these presents, no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment and that said assignor has good and full right and lawful authority to sell and convey the same in the manner herein set forth.

AND for the same consideration, the said assignor hereby covenants and agrees to and with said assignee, its successors, legal representatives and assigns, that said assignor will, whenever counsel of said assignee, or the counsel of its successors, legal representatives and assigns, shall advise that any proceeding in connection with said invention, or said application for Letters Patent, or any proceeding in connection with Letters Patent for said invention in any country, including interference proceedings, is lawful and desirable, or that any division, continuation or continuation-in-part of any application for Letters Patent or any reissue or extension of any Letters Patent, to be obtained thereon, is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of Letters Patent for said invention, without charge to said assignee, its successors, legal representatives and assigns, but at the cost and expense of said assignee, its successors, legal representatives and assigns.

AND said assignor hereby requests the Commissioner of Patents to issue said Letters Patent of the United States to Teikoku Pharma USA, Inc. and Teikoku Seiyaku Kabushiki Kaisha as the joint assignees of said invention and the Letters Patent to be issued thereon for the use and behalf of Teikoku Pharma USA, Inc. and Teikoku Seiyaku Kabushiki Kaisha, their respective successors, legal representatives and assigns.

Date

6/17/10

Assignor:



Ichiro Mori, Executive Vice President and Chief Operating Officer,
Teikoku Pharma USA, Inc.

PATENT

RECORDED: 06/28/2010

REEL: 024605 FRAME: 0131